Stock CBMG CELLULAR BIOMEDICINE GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Cellular Biomedicine Group, Inc.

Equities

CBMG

US15117P1021

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer
CI
Cellular Biomedicine Group Announces FDA Clearance of Investigational New Drug Application for Novel TIL Therapy C-TIL051
CI
Cellular Biomedicine Group Inc Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
CI
Cellular Biomedicine Group Inc. Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
CI
Cellular Biomedicine Group, Inc. announced that it has received $120 million in funding from CICC Capital Management Co., Ltd., AstraZeneca PLC, Investment Arm, Yunfeng Capital, GIC Pte. Ltd., TF Capital, Sequoia China Investment Management LLP and other investors
CI
Hillhouse Capital Provides Information to Shareholders of Hillhouse Capital
CI
Cellular Biomedicine : Completes Merger with CBMG Holdings; Shares to No Longer Trade on Nasdaq
MT
CELLULAR BIOMEDICINE GROUP, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Cellular Biomedicine Group :, Inc. Announces Completion of Merger
PR
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from S&P Global BMI Index
CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from S&P TMI Index
CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from NASDAQ Composite Index
CI
A consortium of buyers completed the acquisition of remaining 52.34% stake in Cellular Biomedicine Group, Inc. from a group of shareholders.
CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Defensive Index
CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Dynamic Index
CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Growth-Defensive Index
CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Value-Defensive Index
CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Index
CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 3000 Index
CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2500 Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CBMG Stock
  4. News Cellular Biomedicine Group, Inc.